- Home
- IPHA vs SSSS Comparison
IPHA vs SSSS Comparison
Compare IPHA & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- SSSS
- Stock Information
- Founded
- IPHA 1999
- SSSS 2010
- Country
- IPHA France
- SSSS United States
- Employees
- IPHA N/A
- SSSS N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- SSSS Finance: Consumer Services
- Sector
- IPHA Health Care
- SSSS Finance
- Exchange
- IPHA Nasdaq
- SSSS Nasdaq
- Market Cap
- IPHA 160.1M
- SSSS 138.2M
- IPO Year
- IPHA 2019
- SSSS N/A
- Fundamental
- Price
- IPHA $2.05
- SSSS $9.12
- Analyst Decision
- IPHA Strong Buy
- SSSS Strong Buy
- Analyst Count
- IPHA 1
- SSSS 4
- Target Price
- IPHA $11.00
- SSSS $9.50
- AVG Volume (30 Days)
- IPHA 14.6K
- SSSS 184.0K
- Earning Date
- IPHA 09-17-2025
- SSSS 11-06-2025
- Dividend Yield
- IPHA N/A
- SSSS 10.95%
- EPS Growth
- IPHA N/A
- SSSS N/A
- EPS
- IPHA N/A
- SSSS 2.22
- Revenue
- IPHA $14,839,695.00
- SSSS $2,784,381.00
- Revenue This Year
- IPHA $350.96
- SSSS $6.95
- Revenue Next Year
- IPHA $32.92
- SSSS N/A
- P/E Ratio
- IPHA N/A
- SSSS $4.11
- Revenue Growth
- IPHA N/A
- SSSS N/A
- 52 Week Low
- IPHA $1.29
- SSSS $3.77
- 52 Week High
- IPHA $3.51
- SSSS $9.50
- Technical
- Relative Strength Index (RSI)
- IPHA 46.87
- SSSS 64.75
- Support Level
- IPHA $1.93
- SSSS $8.99
- Resistance Level
- IPHA $2.19
- SSSS $9.50
- Average True Range (ATR)
- IPHA 0.11
- SSSS 0.18
- MACD
- IPHA -0.01
- SSSS 0.03
- Stochastic Oscillator
- IPHA 49.66
- SSSS 57.78
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.